Indication
Metastatic Breast Cancer
12 clinical trials
27 products
3 drugs
Clinical trial
A Phase III Randomized, Double-blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast CancerStatus: Completed, Estimated PCD: 2017-08-21
Product
TamoxifenProduct
AnastrozoleProduct
GoserelinProduct
RibociclibProduct
LetrozoleProduct
PlaceboProduct
AZD2014Product
FulvestrantClinical trial
A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination With Intramuscular (IM) Fulvestrant to Patients With Estrogen Receptor Positive (ER+) Advanced, Metastatic Breast CancerStatus: Active (not recruiting), Estimated PCD: 2016-08-04
Clinical trial
A Randomized, Controlled Phase Ⅲ Study of Paclitaxel Polymeric Micelles for Injection Versus Physician's Choice(TPC) in Human Epidermal Growth Factor Receptor 2-negative (HER2-) Metastatic Breast Cancer (MBC) Subjects Who Have Failed at Least Two Previous Chemotherapy Regimens.Status: Recruiting, Estimated PCD: 2025-07-01
Product
CapecitabineProduct
PaclitaxelProduct
Eribulin MesilateProduct
Gemcitabine HydrochlorideProduct
Vinorelbine TartrateClinical trial
A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients With Germline or Somatic BRCA1/2 Mutations.Status: Completed, Estimated PCD: 2021-10-08
Product
OlaparibClinical trial
Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases：a Single-arm,Prospective,Phase II StudyStatus: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
Phase I/II Study of Stereotactic Radiation and Abemaciclib in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain MetastasesStatus: Recruiting, Estimated PCD: 2024-12-31
Product
AbemaciclibProduct
Endocrine therapyClinical trial
Phase III Randomized Multicenter Trial Comparing Continued Maintenance Therapy With the Bevacizumab + Taxane Versus Bevacizumab + Substituting Exemestane in Patients With Metastatic Breast Cancer or Locally Advanced With Estrogen Receptor Positive and Having at Least a Stable Disease After 16 to 18 Weeks of Treatment With Bevacizumab + Taxane.Status: Terminated, Estimated PCD: 2014-06-01
Drug
TiragolumabDrug
AtezolizumabProduct
ExemestaneClinical trial
A Phase 2 Study of Etirinotecan Pegol (NKTR-102) in Patients With Refractory Brain Metastases and Advanced Lung Cancer or Metastatic Breast Cancer (MBC)Status: Completed, Estimated PCD: 2018-09-08
Product
Pegylated IrinotecanClinical trial
Trans-RosaLEE Study: a Biomarker-directed, Translational Study of High-throughput Molecular Profiling of HR+/HER2- Metastatic Breast Cancer Treated With Endocrine Therapy and Ribociclib.Status: Recruiting, Estimated PCD: 2026-04-01
Product
Pre-treatment biopsyClinical trial
Phase I/II Trial of Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)Status: Active (not recruiting), Estimated PCD: 2024-11-01
Product
PalbociclibProduct
BicalutamideProduct
Post Treatment BiopsyProduct
Pre treatment blood samplingClinical trial
A Randomized Phase II Study Evaluating Different Schedules of Nab-Paclitaxel in Metastatic Breast Cancer (SNAP Trial)Status: Completed, Estimated PCD: 2016-05-01
Product
nab-PaclitaxelClinical trial
DETECT IV - A Prospective, Multicenter, Open-label, Phase II Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).Status: Completed, Estimated PCD: 2024-01-10
Drug
AN0025